Related Experiment Video

Updated: Aug 15, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

Somatostatin analogs in the diagnosis and treatment of cancer

Steven W J Lamberts1, Wouter W de Herder, Leo J Hofland

  • 1Dept Medicine, Erasmus Medical Centre, 40 Dr. Molewaterplein, 3015 GD Rotterdam, The Netherlands. lamberts@inw3.azr.nl

Trends in Endocrinology and Metabolism: TEM
|November 15, 2002
PubMed

Insights

Somatostatin analogs target somatostatin receptors (sst) on tumors, aiding in hormone control and tumor growth management. New research explores subtype-specific analogs for targeted therapies and improved patient outcomes.

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • Significant advancements have been made in understanding somatostatin receptors (sst) and their role in human tumors.
  • Somatostatin analogs like octreotide primarily bind to sst(2), effectively managing hormone hypersecretion in conditions such as acromegaly and neuroendocrine tumors.
  • sst(2) expression on tumors allows for in vivo imaging using radiolabeled octreotide.

Purpose of the Study:

  • To review the current understanding of somatostatin receptor biology and function in human tumors.
  • To highlight the therapeutic applications of somatostatin analogs in managing hormone-secreting tumors and controlling tumor growth.
  • To discuss the potential of targeted therapies using somatostatin analogs for chemo- and radiotherapy and the significance of subtype-specific analogs.

Main Methods:

  • Review of existing literature on somatostatin receptors and their analogs.
  • Analysis of clinical data regarding the efficacy of octreotide in treating specific endocrine tumors.
  • Discussion of emerging targeted therapy strategies involving somatostatin analogs.

Main Results:

  • Somatostatin analogs, particularly octreotide, demonstrate efficacy in controlling hormone hypersecretion and tumor growth in various neuroendocrine tumors.
  • In vivo imaging of sst(2)-positive tumors is feasible using radiolabeled octreotide.
  • Targeted chemo- and radiotherapy utilizing somatostatin analogs are under investigation for enhanced tumor treatment.

Conclusions:

  • Somatostatin receptors play a crucial role in the management of specific human tumors.
  • Somatostatin analogs offer therapeutic benefits for hormone hypersecretion and tumor growth control.
  • Future development of subtype-specific somatostatin analogs holds promise for more targeted and effective anti-tumor strategies.

More Related Videos

Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids09:43

Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids

Published on: October 14, 2019

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...